COVID-19 Guidance

The ACR has developed new clinical guidance documents for pediatric and adult patients in the context of the COVID-19 pandemic.

ACR Town Hall: COVID-19 Vaccination, Immunosuppression and Rheumatic Disease - Wednesday, August 4

Join us on August 4 from 7:00–8:00 PM ET for the upcoming ACR town hall, COVID-19 Vaccination, Immunosuppression and Rheumatic Disease. The town hall will focus on the COVID-19 vaccines' effectiveness in immunosuppressed and rheumatic disease patients. Find out what we are learning from real-world data collection efforts and ask questions of the expert panel. The panel consists of Marcus Snow MD, Kwas Houston MD, Alfred Kim MD, PhD, and Jean Liew, MD, MS. We will also be joined by Michael R. Anderson, MD, MBA, FAAP, FCCM, FAARC, a key leader on the COVID-19 monoclonal antibody therapeutics team who has been deployed with the federal COVID-19 monoclonal antibody administration team.

Register for Town Hall

COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases (RMDs)

The ACR has developed new guidance for rheumatology providers on the use of the COVID-19 vaccine for patients with rheumatic and musculoskeletal diseases (RMDs). All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.

COVID-19 Vaccine Clinical Guidance Summary - Recommendations updated June 19, 2021

American College of Rheumatology Guidance for COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases – Version 2 Published June 15, 2021
How to cite this article: Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases – Version 2. Arthritis Rheumatol 2021. doi:
https://onlinelibrary.wiley.com/doi/full/10.1002/art.41877

ACR on Air Podcast with lead author, Jeffrey Curtis, MD, MPH 

ACR COVID-19 Vaccine Guidance Town Hall Recording

Press Release: ACR COVID-19 Vaccine Guidance Recommends Vaccination, Addresses Immunosuppressant Drugs & Patient Concerns

Clinical Guidance for Adult Patients with Rheumatic Diseases

Clinical guidance for the care of adult patients with rheumatic diseases during the COVID-19 pandemic include patients with a documented COVID-19 infection, those who are stable following exposure to SARS-CoV-2 (but without known infection), and patients who are stable with no infection or exposure. The recommendations address various treatment options and provide general guidance, as well as direction for when to start, stop, or reduce medications. All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.

COVID-19 Clinical Guidance Summary for Adult Patients with Rheumatic Diseases   Updated - February 1, 2021

American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3  Published - December 5, 2020 How to cite this article: Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 3. Arthritis Rheumatol 2021; 73; e1-e12. doi: https://onlinelibrary.wiley.com/doi/10.1002/art.41437.

Clinical Guidance for Pediatric Patients

The clinical guidance documents for pediatric patients in the context of the COVID-19 pandemic include the care of children with pediatric rheumatic disease, and management of inflammatory syndromes in children with recent or concurrent infections with SARS-CoV-2, specifically Multisystem Inflammatory Syndrome in Children (MIS-C). All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.

The recommendations for pediatric rheumatology patients address various treatment options and provide general guidance, as well as direction for when to start, stop or reduce medications.

The recommendations for MIS-C focus on general guidance, diagnostic evaluation, and therapy options, as well as comparing and contrasting the features of MIS-C and Kawasaki Disease. For hyperinflammation in COVID-19, the recommendations also focus on general guidance, as well as immunomodulatory treatment.

COVID-19 Clinical Guidance Summary for Pediatric Patients with Rheumatic Disease   Updated - May 25, 2021. Link to version 2 manuscript added June 25, 2021.

ACR Guidance for the Management of Children with Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 2   Published - June 10, 2021  How to cite this article: Wahezi DW, Lo MS, Rubinstein TB, Ringold S, Ardoin SP, Downes KJ, et al. American College of Rheumatology Guidance for the Management of Children with Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 2. Arthritis Rheumatol 72; 2020; 1809-1819. doi: https://onlinelibrary.wiley.com/doi/10.1002/art.41772.

Clinical Guidance Summary for Pediatric Patients with MIS-C Associated with SARS-CoV-2 and Hyperinflammation in COVID-19   Updated - November 9, 2020

ACR Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS‐C) Associated with SARS‐CoV‐2 and Hyperinflammation in COVID‐19. Version 2   Published - December 5, 2020  How to cite this article: Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS‐C) Associated with SARS‐CoV‐2 and Hyperinflammation in COVID‐19. Version 2. Arthritis Rheumatol. doi: https://onlinelibrary.wiley.com/doi/full/10.1002/art.41616.

 


ACR Guideline and Criteria App

You can also access the clinical guidance information on your iOS or Android mobile device. Download the free ACR Guideline and Criteria App on the App Store or Google Play.

© 2021 American College of Rheumatology.  All rights reserved.  Website & Privacy Policies | Sitemap | Help | Contact Us